Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0, Biomarker Study Evaluating Biomarkers for the Fractalkine System and the Effect of KAND567 on these Biomarkers in in Patients with Lymphoma

Trial Profile

A Phase 0, Biomarker Study Evaluating Biomarkers for the Fractalkine System and the Effect of KAND567 on these Biomarkers in in Patients with Lymphoma

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 09 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 09 Feb 2019 According to a Kancera media release, this study has been carried out by researchers at Karolinska Institutet in collaboration with Kancera.
    • 09 Feb 2019 Status changed from recruiting to completed, according to a Kancera media release.
    • 09 Feb 2019 Results presented in a Kancera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top